目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product& Service
1.2.2. Application
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Italy
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Cell Therapy Genes Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Cell Therapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTEL Analysis

Chapter 4. U.S. Cell therapy Market Therapy Type Estimates & Trend Analysis
4.1. U.S. Cell Therapy Market Therapy Type Dashboard
4.2. U.S. Cell Therapy Market Therapy Type Movement Analysis
4.3. U.S. Cell Therapy Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.4. Allogeneic Cell Therapy
4.4.1. Allogeneic Cell Therapy Market, 2018 - 2030 (USD Million)
4.4.2. Stem Cell Therapies
4.4.2.1. Stem Cell Therapies Market, 2018 - 2030 (USD Million)
4.4.2.2. Hematopoeitic Stem Cell Therapies
4.4.2.2.1. Hematopoeitic Stem Cell Therapies, 2018 - 2030 (USD Million)
4.4.2.3. Mesenchymal Stem Cell Therapies
4.4.2.3.1. Mesenchymal Stem Cell Therapies, 2018 - 2030 (USD Million)
4.4.3. Non-Stem Cell Therapies
4.4.3.1. Non-Stem Cell Therapies, 2018 - 2030 (USD Million)
4.4.3.2. Keratinocytes & Fibroblast-Based Therapies
4.4.3.2.1. Keratinocytes & Fibroblast-Based Therapies, 2018 - 2030 (USD Million)
4.4.3.3. Other Non-stem Cell Therapies
4.4.3.3.1. Other Non-Stem Cell Therapies, 2018 - 2030 (USD Million)
4.5. Autologous Cell Therapy
4.5.1. Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
4.5.2. T-Cell Therapies
4.5.2.1. T-Cell Therapies Market, 2018 - 2030 (USD Million)
4.5.2.2. CAR-T Cell Therapy
4.5.2.2.1. CAR-T Cell Therapy, 2018 - 2030 (USD Million)
4.5.2.3. T-Cell Receptor (TCR)
4.5.2.3.1. T-Cell Receptor (TCR), 2018 - 2030 (USD Million)
4.5.3. Others
4.5.3.1. Other Autologous Non-Stem Cell Therapies, 2018 - 2030 (USD Million)

Chapter 5. U.S. Cell Therapy Market: Therapeutic Area Estimates & Trend Analysis
5.1. U.S. Cell Therapy Market Therapeutic Area Dashboard
5.2. U.S. Cell Therapy Market Therapeutic Area Movement Analysis
5.3. U.S. Cell Therapy Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4. Oncology
5.4.1. Oncology Therapies, 2018 - 2030 (USD Million)
5.5. Dermatology
5.5.1. Dermatology Therapies, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Other Therapies, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.2.1. Key company market share analysis, 2023
6.3. Vendor Landscape
6.3.1. Gilead Sciences, Inc.
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Product benchmarking
6.3.1.4. Strategic initiatives
6.3.2. Selecta Bioscience
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Product benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Bristol-Myers Squibb Company
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Product benchmarking
6.3.3.4. Strategic initiatives
6.3.4. CARGO Therapeutics, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Johnson & Johnson
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Atara Biotherapeutics, Inc
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Nkarta, Inc
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Cellular Biomedicine Group, Inc
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. Vertex Pharmaceuticals Incorporated
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Aurion Biotech
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives

List of Tables
Table 1. List of abbreviations
Table 2. U.S. Cell Therapy Market, Therapy Type, 2018 - 2030 (USD Million)
Table 3. U.S. Cell Therapy Market, Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Cell therapy genes market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 PESTEL analysis
Fig. 13 Porter’s Five Forces analysis
Fig. 14 U.S. Cell Therapy: Product& service outlook and key takeaways
Fig. 15 U.S. Cell Therapy Market: Product& service movement analysis & market share 2023 & 2030
Fig. 16 Allogeneic Therapies, 2018 - 2030 (USD Million)
Fig. 17 Stem Cell Therapies, 2018 - 2030 (USD Million)
Fig. 18 Hematopoietic Stem Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 19 Mesenchymal Stem Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 20 Non-Stem Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 21 Keratinocyte & Fibroblast-Based Therapies Market, 2018 - 2030 (USD Million)
Fig. 22 Other Non-Stem Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 23 Autologous Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 24 Autologous Stem-Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 25 BM, Blood, & Umbilical Cord-Derived Stem Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 26 Adipose Derived Cells Market, 2018 - 2030 (USD Million)
Fig. 27 Others Market, 2018 - 2030 (USD Million)
Fig. 28 Autologous Non-Stem Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 29 T-Cell Therapies Market, 2018 - 2030 (USD Million)
Fig. 30 CAR T Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 31 T Cell Receptor (TCR)-Based Market, 2018 - 2030 (USD Million)
Fig. 32 Other Autologous Non-Stem-Cell Therapies Market, 2018 - 2030 (USD Million
Fig. 33 Fig U.S. Cell Therapy Market: Therapeutic Area outlook and key takeaways
Fig. 34 Fig U.S. Cell Therapy Market: Therapeutic Area movement analysis & market share 2023 & 2030
Fig. 35 Cell therapy genes market: Application movement analysis
Fig. 36 Oncology Market, 2018 - 2030 (USD Million)
Fig. 37 Cardiovascular Disease (CVD) Market, 2018 - 2030 (USD Million)
Fig. 38 Musculoskeletal Disorders Market, 2018 - 2030 (USD Million)
Fig. 39 Dermatology Market, 2018 - 2030 (USD Million)
Fig. 40 Others Market, 2018 - 2030 (USD Million)